Genprex, Inc.

GNPX · Nasdaq · United States

Share price · GNPX

$1.71-2.24 (-56.71%) 3M

close as of 2026-11-18 · 24h delayed · vol 62K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GNPX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-12.1%
  2. 30 Oct 2026+9.8%
  3. 28 Sep 2026-14.6%
  4. 3 Aug 2026-20.7%
  5. 30 Jul 2026-14.9%
  6. 16 Jul 2026-25.9%

    Nothing announced by GNPX that day or the session before.

  7. 14 Jul 2026-13.5%
  8. 18 Jun 2026+22.5%
  9. 15 Jun 2026-24.0%
  10. 23 Feb 2026+27.5%

Share of unusual movement by asset

For each asset, the share of GNPX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
TUSC2 (tumor suppressor gene replacement)Gene therapy / editing
Non-Small Cell Lung CancerSmall Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Quaratusugene Ozeplasmid · ReqorsaPhase 1/2Small Cell Lung Cancer Extensive Stage
Est. primary completion 2027-12 · NCT05703971 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Quaratusugene Ozeplasmid · ReqorsaPhase 1/2Carcinoma, Non-Small Cell Lung
Est. primary completion 2028-03 · NCT04486833 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$2.7M$15M$4.2M-$2.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$2.7M$15M$4.5M-$5.1M operating cash flowreport ↗
2026-Q1—$2.8M$18M$4.5M-$3.1M operating cash flowreport ↗
2025-Q3—$2.2M$1.1M$3.8M-$3.2M operating cash flowreport ↗
2025-Q2—$2.5M$1.4M$4.7M-$3.9M operating cash flowreport ↗
2025-Q1—$2.5M$3.5M$4.0M-$4.2M operating cash flowreport ↗
2024-Q3—$2.8M$1.5M$4.3M-$2.2M operating cash flowreport ↗
2024-Q2—$1.7M$2.5M$6.5M-$5.8M operating cash flowreport ↗
2024-Q1—$3.3M$8.2M$6.0M-$5.3M operating cash flowreport ↗
2023-Q3—$4.6M$12M$7.8M-$4.7M operating cash flowreport ↗
2023-Q2—$4.0M$10.0M$8.0M-$8.1M operating cash flowreport ↗
2023-Q1—$5.3M$18M$9.2M-$6.9M operating cash flowreport ↗
2022-Q3$0$3.6M$26M$6.1M-$4.6M operating cash flowreport ↗
2022-Q2$0$2.7M$30M$5.2M-$4.5M operating cash flowreport ↗
2022-Q1$0$1.9M$35M$5.7M-$4.1M operating cash flowreport ↗
2021-Q3$0$1.4M$42M$3.4M-$2.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.4M$7.8M$4.1M-$15M operating cash flowreport ↗

For FY2025, Genprex did not disclose revenue, and prior-year revenue was also not disclosed. R&D spend was $9.429M, down 10.5% YoY from $10.535M. Cash and equivalents totaled $7.831M. Net income/loss was not disclosed, and quarterly net burn was $16.229M.

The company continued enrolling the Phase 2a expansion of Acclaim-1 (REQORSA plus Tagrisso) and the Phase 2 expansion of Acclaim-3 (REQORSA plus Tecentriq), with interim analyses expected in the second half of 2026; Acclaim-2 was closed to new enrollment. In diabetes, Genprex formed Convergen Biotech as a wholly-owned subsidiary to support separation of its diabetes program, and after a February 2026 FDA meeting it plans to advance preclinical and toxicology studies and cGMP manufacturing toward an IND. During 2025 the company effected reverse stock splits, raised approximately $10.8M in net proceeds through its ATM program, and regained Nasdaq compliance.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$1.6M—-$17M operating cash flowreport ↗
2023-FY$0$18M$6.7M$7.7M-$25M operating cash flowreport ↗
2022-FY$0$12M$21M$5.9M-$18M operating cash flowreport ↗
2021-FY$0$8.6M$39M$4.9M-$14M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($22). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-04-14LONGNECKER BRENT M · directorOpen-market sale8$1.23$10Form 4
2026-04-14LONGNECKER BRENT M · directorOpen-market sale10$1.23$12Form 4
2026-02-27Confer Ryan M. · director, President, CEO and CFOTax withholding9,330$2.00$19KForm 4
2026-02-27Berger Mark Stanley · Chief Medical OfficerTax withholding7,168$2.00$14KForm 4
2025-12-22Wilson William R Jr. · directorAward / grant9,000——Form 4
2025-12-22LONGNECKER BRENT M · directorAward / grant9,000——Form 4
2025-12-22Confer Ryan M. · director, President, CEO and CFOAward / grant45,000——Form 4
2025-12-22Berger Mark Stanley · Chief Medical OfficerAward / grant28,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 27 reporting institutions held 0.1M shares ($156K, 11.4% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC33,372$60K
2Mayflower Financial Advisors, LLC20,000$36K
3MANCHESTER FINANCIAL INC20,000$36K
4VANGUARD CAPITAL MANAGEMENT LLC5,950$11K
5JONES FINANCIAL COMPANIES LLLP2,105$4K
6CITIGROUP INC2,039$4K
7Cheviot Value Management, LLC1,000$2K
8Sound Income Strategies, LLC1,000$2K
9OSAIC HOLDINGS, INC.232$417
10Bernard Wealth Management Corp.200$362
11BlackRock, Inc.188$340
12HARBOUR INVESTMENTS, INC.120$218
13SBI Securities Co., Ltd.48$87
14HighMark Wealth Management LLC10$18
15MORGAN STANLEY6$11